Low adherence to antidepressants is associated with increased mortality in Parkinson disease patients

Abstract

Our findings suggest that poor adherence to AD is associated with increased all-cause mortality in people with PD. Given the high prevalence of depression and AD effectiveness, efforts to promote adherence should be prioritized in clinical practice.

Adherence to antidepressant medications is associated with reduced premature mortality in patients with cancer: A nationwide cohort study

“…Similarly to our previous reports on mortality in other AD‐using populations (Krivoy et al, ; Krivoy et al, ; Krivoy et al, ; Shoval et al, ), our unadjusted analyses in the present study showed an increased rate of death in the higher adherence levels. As previously discussed broadly in these publications, we attribute this finding mainly to a more drug adherent behavior in the older and highly comorbid patients, therefore such findings demonstrate the importance of having the capability to adjust for important confounders.…”

“…This relationship is systematically repeated in all subtypes of cancer we studied, except for melanoma. Similarly to our previous studies in the general population and in certain other major physical disorders (Krivoy et al, ; Krivoy et al, ; Krivoy et al, ; Shoval et al, ), the beneficial effect of adherence to AD may be at least equally important in the high‐risk population of patients with cancer. Psychiatrists, Oncologists, and primary‐care physicians should step up their efforts to sustain and enhance their patients' adherence to AD, as it may be associated with increased life expectancy.…”

“…Adherence is reported as a percentage score for each patient. Similarly to previous literature (Krivoy et al, ; Krivoy et al, ; Krivoy et al, ; Shoval et al, ), patients with adherence below 20% were considered nonadherent, those with 20–50% adherence were considered poorly adherent, those with 50–80% were considered to have a moderate adherence and patients with adherence above 80% were considered to have good adherence. In accordance with previous research, we did not model adherence as a continuous variable, since our previous study demonstrated no superiority when considering adherence as a continuous versus the categorical variables described here (Krivoy et al, ).…”

“…Patient adherence rates to AD reflect the actual longitudinal consumption of AD and are measured as a continuous variable, rather than dichotomous use or nonuse which is far less informative. Previous nationwide cohort studies have found a beneficial effect of good adherence to AD for reducing premature mortality in the general population (Krivoy et al, ), cardiovascular patients (Krivoy et al, ), Parkinson Disease (Shoval et al, ), and stroke patients (Krivoy et al, ). To the best of our knowledge, no previous study has investigated the association between AD adherence and mortality in people with cancer.…”

All-cause mortality with current and past use of antidepressants or benzodiazepines after major osteoporotic and hip fracture

“…Therefore, we cannot explain the effects by direct pharmacological action. In previous research, it was reported that good adherence is associated with a decreased mortality [37, 38], while other studies report that poor adherence is associated with an increased mortality risk ([39]. However, in our study, data regarding persistence and reasons or causes of stopping the antidepressants or benzodiazepines were not available.…”